NCT04974983View on ClinicalTrials.gov

Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma

CompletedOBSERVATIONAL
Enrollment

203

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

June 30, 2020

Study Completion Date

August 30, 2020

Conditions
GlioblastomaAngiogenesis
Interventions
OTHER

Observation of neurological deficits

Observation of neurological deficits

Trial Locations (1)

93042

University Hospital Regensburg, Regensburg

All Listed Sponsors
lead

University Hospital Regensburg

OTHER

NCT04974983 - Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter